NCT00526279

Brief Summary

To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2007

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 10, 2007

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2008

Completed
Last Updated

December 1, 2010

Status Verified

November 1, 2010

Enrollment Period

1.2 years

First QC Date

September 6, 2007

Last Update Submit

November 30, 2010

Conditions

Hypertension

Keywords

HypertensionAtacand/Atacand plusCOMBATComplianceNaturalisticObservational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Primary Care

You may qualify if:

  • Patients who have consented to participation/data release in this study
  • Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

You may not qualify if:

  • Secondary hypertension requiring therapy other than antihypertensive medication
  • Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
  • Women in pregnancy or lactation
  • Patients enrolled in any other studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Research Site

Seoul, Jongro-gu, South Korea

Location

Research Site

Seoul, Kangnam-gu, South Korea

Location

Research Site

Seoul, Songpa-gu, South Korea

Location

MeSH Terms

Conditions

HypertensionPatient Compliance

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Hyunah Caroline Choi

    AstraZeneca Korea

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 6, 2007

First Posted

September 10, 2007

Study Start

June 1, 2007

Primary Completion

August 1, 2008

Study Completion

August 1, 2008

Last Updated

December 1, 2010

Record last verified: 2010-11

Locations

KR(3)